Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PCYC's Cash to Debt is ranked higher than
94% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. PCYC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PCYC' s 10-Year Cash to Debt Range
Min: 0.1  Med: 10000.00 Max: 26993.8
Current: No Debt
0.1
26993.8
Equity to Asset 0.80
PCYC's Equity to Asset is ranked higher than
66% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PCYC: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
PCYC' s 10-Year Equity to Asset Range
Min: 0.6  Med: 0.89 Max: 0.98
Current: 0.8
0.6
0.98
Interest Coverage No Debt
PCYC's Interest Coverage is ranked higher than
89% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PCYC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PCYC' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 54.54
M-Score: -0.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 13.23
PCYC's Operating margin (%) is ranked higher than
82% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. PCYC: 13.23 )
Ranked among companies with meaningful Operating margin (%) only.
PCYC' s 10-Year Operating margin (%) Range
Min: -24376.8  Med: -1230.77 Max: 37.64
Current: 13.23
-24376.8
37.64
Net-margin (%) 8.82
PCYC's Net-margin (%) is ranked higher than
77% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. PCYC: 8.82 )
Ranked among companies with meaningful Net-margin (%) only.
PCYC' s 10-Year Net-margin (%) Range
Min: -23291.71  Med: -975.44 Max: 25.76
Current: 8.82
-23291.71
25.76
ROE (%) 9.57
PCYC's ROE (%) is ranked higher than
83% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. PCYC: 9.57 )
Ranked among companies with meaningful ROE (%) only.
PCYC' s 10-Year ROE (%) Range
Min: -318.92  Med: -32.38 Max: 17.64
Current: 9.57
-318.92
17.64
ROA (%) 7.63
PCYC's ROA (%) is ranked higher than
86% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. PCYC: 7.63 )
Ranked among companies with meaningful ROA (%) only.
PCYC' s 10-Year ROA (%) Range
Min: -127.89  Med: -29.86 Max: 13.57
Current: 7.63
-127.89
13.57
ROC (Joel Greenblatt) (%) 345.15
PCYC's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. PCYC: 345.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PCYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5354.61  Med: -923.10 Max: 460.92
Current: 345.15
-5354.61
460.92
Revenue Growth (3Y)(%) 305.60
PCYC's Revenue Growth (3Y)(%) is ranked higher than
99% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PCYC: 305.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PCYC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 305.6
Current: 305.6
0
305.6
» PCYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PCYC Guru Trades in Q2 2014

Ken Fisher 5,114 sh (New)
Joel Greenblatt 79,089 sh (+724.62%)
Murray Stahl 8,783 sh (+27.96%)
Jim Simons 60,400 sh (+26.62%)
Mariko Gordon 4,000 sh (unchged)
Steven Cohen 574,900 sh (unchged)
Mariko Gordon Sold Out
PRIMECAP Management 2,313,039 sh (-2.84%)
» More
Q3 2014

PCYC Guru Trades in Q3 2014

Joel Greenblatt Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
PRIMECAP Management 2,311,039 sh (-0.09%)
Murray Stahl 7,003 sh (-20.27%)
Ken Fisher 3,244 sh (-36.57%)
» More
Q4 2014

PCYC Guru Trades in Q4 2014

Joel Greenblatt 2,619 sh (New)
Jim Simons 108,000 sh (New)
Ken Fisher 3,264 sh (+0.62%)
PRIMECAP Management 2,310,539 sh (-0.02%)
Murray Stahl 6,401 sh (-8.60%)
» More
Q1 2015

PCYC Guru Trades in Q1 2015

Mario Gabelli 27,750 sh (New)
Paul Tudor Jones 1,951 sh (New)
Eric Mindich 658,020 sh (New)
Louis Moore Bacon 15,000 sh (New)
Jim Simons 331,700 sh (+207.13%)
Joel Greenblatt Sold Out
Ken Fisher Sold Out
PRIMECAP Management 2,284,039 sh (-1.15%)
Murray Stahl 3,305 sh (-48.37%)
» More
» Details

Insider Trades

Latest Guru Trades with PCYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Pharmacyclics Inc

Eric Mindich Increases His Most Valuable Stake in First Quarter
Eric Mindich (Trades, Portfolio), founder and CEO of hedge fund Eton Park Capital Management, has a history of early success. At the age of 27, he was the youngest partner in Goldman Sachs’ (NYSE:GS) history. He left Goldman Sachs a decade later to start Eton Park – one of the largest fund launches in history at $3.5 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 291.60
PCYC's P/E(ttm) is ranked lower than
92% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. PCYC: 291.60 )
Ranked among companies with meaningful P/E(ttm) only.
PCYC' s 10-Year P/E(ttm) Range
Min: 35.9  Med: 122.79 Max: 496.74
Current: 291.6
35.9
496.74
Forward P/E 57.14
PCYC's Forward P/E is ranked lower than
82% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. PCYC: 57.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 290.30
PCYC's PE(NRI) is ranked lower than
93% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. PCYC: 290.30 )
Ranked among companies with meaningful PE(NRI) only.
PCYC' s 10-Year PE(NRI) Range
Min: 35.77  Med: 122.65 Max: 479
Current: 290.3
35.77
479
P/B 22.48
PCYC's P/B is ranked lower than
93% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. PCYC: 22.48 )
Ranked among companies with meaningful P/B only.
PCYC' s 10-Year P/B Range
Min: 0.27  Med: 6.74 Max: 35.11
Current: 22.48
0.27
35.11
P/S 25.05
PCYC's P/S is ranked lower than
68% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. PCYC: 25.05 )
Ranked among companies with meaningful P/S only.
PCYC' s 10-Year P/S Range
Min: 10.87  Med: 49.43 Max: 617
Current: 25.05
10.87
617
PFCF 196.43
PCYC's PFCF is ranked lower than
83% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. PCYC: 196.43 )
Ranked among companies with meaningful PFCF only.
PCYC' s 10-Year PFCF Range
Min: 8.05  Med: 69.80 Max: 218.11
Current: 196.43
8.05
218.11
POCF 167.47
PCYC's POCF is ranked lower than
89% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. PCYC: 167.47 )
Ranked among companies with meaningful POCF only.
PCYC' s 10-Year POCF Range
Min: 7.89  Med: 62.35 Max: 172.33
Current: 167.47
7.89
172.33
EV-to-EBIT 178.35
PCYC's EV-to-EBIT is ranked lower than
89% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. PCYC: 178.35 )
Ranked among companies with meaningful EV-to-EBIT only.
PCYC' s 10-Year EV-to-EBIT Range
Min: -28.2  Med: 0.50 Max: 400.3
Current: 178.35
-28.2
400.3
Shiller P/E 589.43
PCYC's Shiller P/E is ranked lower than
98% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.33 vs. PCYC: 589.43 )
Ranked among companies with meaningful Shiller P/E only.
PCYC' s 10-Year Shiller P/E Range
Min: 326.84  Med: 717.58 Max: 7580.5
Current: 589.43
326.84
7580.5
Current Ratio 5.54
PCYC's Current Ratio is ranked higher than
57% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. PCYC: 5.54 )
Ranked among companies with meaningful Current Ratio only.
PCYC' s 10-Year Current Ratio Range
Min: 0.14  Med: 12.07 Max: 49.32
Current: 5.54
0.14
49.32
Quick Ratio 5.29
PCYC's Quick Ratio is ranked higher than
57% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. PCYC: 5.29 )
Ranked among companies with meaningful Quick Ratio only.
PCYC' s 10-Year Quick Ratio Range
Min: 0.14  Med: 12.07 Max: 49.32
Current: 5.29
0.14
49.32
Days Inventory 55.59
PCYC's Days Inventory is ranked higher than
76% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. PCYC: 55.59 )
Ranked among companies with meaningful Days Inventory only.
PCYC' s 10-Year Days Inventory Range
Min: 32.23  Med: 344.60 Max: 656.97
Current: 55.59
32.23
656.97
Days Sales Outstanding 34.43
PCYC's Days Sales Outstanding is ranked higher than
75% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. PCYC: 34.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCYC' s 10-Year Days Sales Outstanding Range
Min: 2.39  Med: 20.86 Max: 54.75
Current: 34.43
2.39
54.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 30.52
PCYC's Price/Net Cash is ranked lower than
85% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. PCYC: 30.52 )
Ranked among companies with meaningful Price/Net Cash only.
PCYC' s 10-Year Price/Net Cash Range
Min: 0.46  Med: 6.33 Max: 1650
Current: 30.52
0.46
1650
Price/Net Current Asset Value 23.64
PCYC's Price/Net Current Asset Value is ranked lower than
83% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. PCYC: 23.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PCYC' s 10-Year Price/Net Current Asset Value Range
Min: 0.46  Med: 5.54 Max: 30.01
Current: 23.64
0.46
30.01
Price/Tangible Book 22.70
PCYC's Price/Tangible Book is ranked lower than
90% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. PCYC: 22.70 )
Ranked among companies with meaningful Price/Tangible Book only.
PCYC' s 10-Year Price/Tangible Book Range
Min: 0.44  Med: 4.33 Max: 28.59
Current: 22.7
0.44
28.59
Price/Projected FCF 15.67
PCYC's Price/Projected FCF is ranked lower than
72% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. PCYC: 15.67 )
Ranked among companies with meaningful Price/Projected FCF only.
PCYC' s 10-Year Price/Projected FCF Range
Min: 7.41  Med: 11.58 Max: 65.87
Current: 15.67
7.41
65.87
Price/Median PS Value 0.51
PCYC's Price/Median PS Value is ranked higher than
85% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. PCYC: 0.51 )
Ranked among companies with meaningful Price/Median PS Value only.
PCYC' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 1.70 Max: 17.3
Current: 0.51
0.26
17.3
Price/Graham Number 16.77
PCYC's Price/Graham Number is ranked lower than
94% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. PCYC: 16.77 )
Ranked among companies with meaningful Price/Graham Number only.
PCYC' s 10-Year Price/Graham Number Range
Min: 3.73  Med: 7.44 Max: 20.08
Current: 16.77
3.73
20.08
Earnings Yield (Greenblatt) (%) 0.60
PCYC's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PCYC: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PCYC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 2.00 Max: 13078.4
Current: 0.6
0.2
13078.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PY2.Germany,
Pharmacyclics Inc was incorporated in Delaware in 1991 and commenced operations in 1992. It is a biopharmaceutical company, engaged in developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases. On November 13, 2013, the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib, PCI-32765) as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and concurrently on November 13, 2013, the Company commercially launched IMBRUVICATM in the United States. The Company has contracted with a third-party logistics company to warehouse IMBRUVICATM and distribute it to wholesalers, distributors, pharmacies, hospitals, and other drug suppliers that ultimately distribute IMBRUVICATM directly to patients. The Company's competitors include pharmaceutical and biotechnology companies, clinical reference laboratories and government agencies, as well as academic research institutions that are pursuing research activities similar to the company. The FDA and applicable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
» More Articles for PCYC

Headlines

Articles On GuruFocus.com
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015 
AbbVie Floats Mega-Bond Deal For Acquisition Funding May 08 2015 
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
Pharmacyclics Posts A Mixed First Quarter Ahead Of Being Acquired By AbbVie May 07 2015 
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Weekly Insider Sells Highlight: PCYC, DIS, AZO, SCI Mar 17 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
own Mar 02 2015 
Weekly 52-Week Highs Highlight: DG, AGN, ADSK, AVGO, PCYC Feb 22 2015 

More From Other Websites
AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript Jul 24 2015
Chi-Med Arthritis Drug Spurs Interest From Potential Partners Jun 18 2015
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015
Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic... May 31 2015
Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly... May 30 2015
ABBVIE INC. Financials May 29 2015
Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for... May 28 2015
AbbVie Accelerates Share Buybacks May 27 2015
Ambarella Leads 3 Top Stocks Bucking The Sell-Off May 26 2015
Pharmacyclics' Imbruvica Gets CHMP's Nod for Full Approval - Analyst Blog May 26 2015
Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck May 26 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
PHARMACYCLICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... May 26 2015
AbbVie Completes Acquisition of Pharmacyclics May 26 2015
The Most Loved Biotechs of Big Hedge Funds May 23 2015
European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA®... May 22 2015
Abbvie specifies breakdown of $21 billion Pharmacyclics deal May 21 2015
Abbvie specifies breakdown of $21 billion Pharmacyclics deal May 21 2015
AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics May 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK